Intravenous NAD+ effectively increased the NAD metabolome, reduced oxidative stress and inflammation, and increased expression of longevity genes safely in elderly humans

Nicotinamide adenine dinucleotide (NAD+) serves  important roles in hydrogen transfer and as the  cosubstrate for poly(ADP-ribose) polymerase (PARPs), the sirtuin (SIRT1-7) family of enzymes, and CD38  glycohydrolases. Recently, intravenous (IV) NAD+  therapy has been used as a holistic approach to treat  withdrawal from addiction, overcome anxiety and depression, and improve overall quality of life with  minimal symptoms between 3-7 days of treatment.  We evaluated repeat dose IV NAD+ (1000 mg) for  6 days in a population of 8 healthy adults between the  ages of 70 and 80 years.  Our data is the first to show that IV NAD+  increases the blood NAD+ metabolome in elderly  humans. We found increased concentrations of  glutathione peroxidase -3 and paraoxonase-1, and decreased concentrations of 8-iso-prostaglandin F2α,  advanced oxidative protein products, protein carbonyl,  C-reactive protein and interleukin 6. We report  significant increases in mRNA expression and activity  of SIRT1, and Forkhead box O1, and reduced acetylated  p53 in peripheral blood mononuclear cells isolated from  these subjects. No major adverse effects were reported  in this study.  The study shows that repeat IV dose of NAD+ is a  safe and efficient way to slow down age-related decline  in NAD+.